Who We Are

Our history

More than 20 years of revolutionary therapies

Seattle Genetics initiates operations in Bothell, Washington.

1998

1999

Our research into anti-CD30 antibodies begins.

2001

Our scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload for our first investigational antibody–drug conjugate (ADC), brentuximab vedotin (ADCETRIS®).

2006

The first clinical trial patient receives brentuximab vedotin (ADCETRIS).

2007

Seagen and Agensys (acquired by Astellas) enter into a collaboration, resulting in the co-development of enfortumab vedotin, an investigational ADC that targets Nectin-4.

2009

Seagen and Takeda agree to globally co-develop and commercialize brentuximab vedotin (ADCETRIS).

2011

ADCETRIS® (brentuximab vedotin receives accelerated approval in the U.S.

Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).

Disease Area: Lymphoma

2012

ADCETRIS is approved in the European Union.

2015

Seagen expands access to ADC technology via collaborations with global biotechnology and pharmaceutical industry leaders.

2016

Our European headquarters opens in Zug, Switzerland.

2017

ADCETRIS (brentuximab vedotin) receives approval for an additional indication in the U.S.

Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).

Disease Area: Lymphoma

2018

20-year anniversary of Seagen.

2018

ADCETRIS (brentuximab vedotin) is approved in the U.S. for 2 additional indications.

Please see full Prescribing Information, including BOXED WARNING for PML, for ADCETRIS (brentuximab vedotin, for injection 50 mg).

Disease Area: Lymphoma

Seagen acquires Cascadian Therapeutics, including the late-stage investigational agent tucatinib.

2019

PADCEV® (enfortumab vedotin-ejfv) receives accelerated approval in the U.S.

Please see full Prescribing Information, including BOXED WARNING for Serious Skin Reactions, for PADCEV (enfortumab vedotin-ejfv, for injection 20 mg & 30 mg vials).

Disease Area: Urothelial Cancer

2019

ADCETRIS is established as a foundation of care and approved in more than 70 countries.

2020

TUKYSA® (tucatinib,) is approved in the U.S. and other countries -- our third approved and first wholly-owned medicine.

Please see full Prescribing Information, for TUKYSA (tucatinib, 50 mg & 150 mg tablets)

Disease Area: Breast Cancer

2020

Seattle Genetics, Inc. changes its name to Seagen Inc. to reflect the transformation of the company from its Seattle roots into a global operation.

2021

TIVDAK® (tisotumab vedotin-tftv) receives accelerated approval in the U.S. – our fourth approved medicine.

Please see full Prescribing Information, including BOXED WARNING for Ocular Toxicity, for TIVDAK (tisotumabe vedotin-tftv, for injection 40 mg).

Disease Area: Cervical Cancer

Our commitment to innovation and making a meaningful impact in cancer care continues.

>